Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 14;S1590-8658(20)30133-X.
doi: 10.1016/j.dld.2020.03.031. Online ahead of print.

COVID-19 Epidemic: Proposed Alternatives in the Management of Digestive Cancers: A French Intergroup Clinical Point of View (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)

Affiliations
Free PMC article

COVID-19 Epidemic: Proposed Alternatives in the Management of Digestive Cancers: A French Intergroup Clinical Point of View (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)

Frederic Di Fiore et al. Dig Liver Dis. .
Free PMC article

Abstract

Introduction: Patients treated for malignancy are considered at risk of severe COVID-19. This exceptional pandemic has affected countries on every level, particularly health systems which are experiencing saturation. Like many countries, France is currently greatly exposed, and a complete reorganization of hospitals is ongoing. We propose here adaptations of diagnostic procedures, therapies and care strategies for patients treated for digestive cancer during the COVID-19 epidemic.

Methods: French societies of gastroenterology and gastrointestinal (GI) oncology carried out this study to answer two main questions that have arisen (i) how can we limit high-risk situations for GI-cancer patients and (ii) how can we limit contact between patients and care centers to decrease patients' risk of contamination while continuing to treat their cancer. All recommendations are graded as experts' agreement according to the level of evidence found in the literature until March 2020.

Results: A proposal to adapt treatment strategies was made for the main GI oncology situations. Considering the level of evidence and the heterogeneous progression of the COVID-19 epidemic, all proposals need to be considered by a multidisciplinary team and implemented with patient consent.

Conclusion: COVID-19 epidemic may significantly affect patients treated for digestive malignancies. Healthcare teams need to consider adapting treatment sequences when feasible and according to the epidemic situation.

Keywords: COVID-19 infection; Chemotherapy; Digestive cancer; French Clinical Practice Guidelines; Surgery.

Conflict of interest statement

Conflict of interest The Authors have no Conflict of interest in digestive oncology topics with COVID-19.

Similar articles

See all similar articles

References

    1. Kim Y.J., Lee E.S., Lee Y.S. High mortality from viral pneumonia in patients with cancer. Infect Dis. 2019;51:502–509.
    1. Chen N., Zhou M., Dong X. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513. - PMC - PubMed
    1. Wu C., Chen X., Cai Y., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med doi 10.1001/jamainternmed.2020.0994
    1. Liang W., Guan W., Chen R., et al. Cancer patients in SARS-CoV -2 infection: a nationwide analysis in China. Lancet Oncol10.1016/S1470-2045(20)30096-6
    1. Spinelli A., Pellino G. COVID-19 pandemic: perspectives on an unfolding crisis. Br J Surg. 2020 doi: 10.1002/bjs.11627. - DOI
Feedback